SPY330.65-3.85 -1.15%
DIA276.52-2.38 -0.85%
IXIC10,793.28-117.00 -1.07%

Citius Pharma Reports Outcome Of Interim Futility Analysis For Phase 3 Mino-Lok Pivotal Trial: 'Data Monitoring Committee recommends continuation of the trial with no changes'

Benzinga · 12/19/2019 13:01